
Pfizer's (PFE) Lorbrena Gets FDA Nod for First
Pfizer Inc. (PFE Quick QuotePFE - Free Report) announced that the FDA has approved its supplemental new drug application (sNDA) for its tyrosine kinase inhibitor cancer drug, Lorbrena (lorlatinib), earlier than expected. The sNDA is seeking label expansion …